Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cephalexin + cefazolin
- Development stage
- Phase 4
- Lead developer
- Pragma Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cephalexin and cefazolin are both first-generation cephalosporin antibiotics that work by inhibiting bacterial cell wall synthesis. They bind to specific penicillin-binding proteins (PBPs) inside bacterial cell walls, inhibiting the third and last stage of bacterial cell wall synthesis, which leads to cell lysis mediated by bacterial cell wall autolytic enzymes. Both antibiotics are effective against a wide spectrum of Gram-positive bacteria, though they differ in administration routes - cephalexin is administered orally while cefazolin is given parenterally (intravenously).
- Brand names
- Keflex + Ancef
- Other names
- cephalexin + cephazolin
02
Targets
Beyond the preview
Go deeper on cephalexin + cefazolin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cephalexin + cefazolin.